[PDF] Top 20 The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema : an indirect comparison in a systematic review

... compare bevacizumab and ranibizumab for treatment of diabetic macular oedema in an indirect ...comparison. Indirect comparisons are subject to potential biases and ... See full document

... This review, however, has ...the effectiveness within drug ...for ranibizumab, pegaptanib, dexamethasone and fl uocinolone, whereas trials for bevacizumab and triamcinolone were generally ... See full document

... Earlier systematic reviews identi fi ed limited evidence on the clinical effectiveness of ...A review by Braithwaite et al 61 (search date August 2010) on anti-VEGF agents identi fi ed one RCT ... See full document

... IVTA was more effective than IVB in the early period, but no significant difference between groups was found at the final visit. IVTA induced significant retinal thinning compared to IVB in ischemic BRVO in the first 3 ... See full document

... in clinical studies, it is critical that the instrument selected provides a valid measurement of the concept of interest in the specific context of use [9–11]; this has become especially relevant in recent years ... See full document

... Macular Edema (FAME) studies were two large prospec- tive, randomized, controlled studies that followed 956 eyes randomized to receive 0.2 µ g/day (low dose) or 0.50 µ g/day (high dose) inserts or sham. After 3 ... See full document

... virtual review of patients ’ OCT scans, such that some face to face referrals may not be necessary, and this would result in more cost-effective care for the ...to clinical governance oversight, if ... See full document

... Abstract: Diabetic macular edema (DME) has shown an increasing prevalence during the past years and is the leading cause of diabetic retinopathy ...in clinical trials conducted both worldwide ... See full document

... of bevacizumab, the mean retinal thickness was decreased to ...six-month bevacizumab course was completed, the mean retinal thickness had again decreased slightly to ...six-month bevacizumab course, ... See full document

... prolonged bevacizumab or ranibizumab therapy results in rapid resolu- tion of subretinal fluid and flattening of pigment epithelial detachments (Figure ... See full document

... Institutional Review Boards of Tokyo Medical University and Ibaraki Medical ...(BCVA), indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, fundus photography, and optical coherence ... See full document

... of ranibizumab for neovascular age-related macular degeneration, which included an independent economic evaluation ...a ranibizumab injection, which, when converted to US dollars on the basis of the ... See full document

... present clinical evidence of efficacy and adverse events of commonly used anti-VEGF drugs for Diabetic Macular ...A systematic review was undertaken from the Medline, Biosis, CINAHL, ... See full document

... and Bevacizumab have been in use for nAMD for some time, with Aflibercept being introduced later [5, ...world effectiveness is cur- rently ...from Ranibizumab or Bevacizumab to Aflibercept is ... See full document

... the ranibizumab PRN ...The relative efficacy (odds ratios) of ranibizumab PRN vs aflibercept—sourced from a network meta-analysis conducted by Régnier et ...as ranibizumab PRN were assumed. ... See full document

... on ranibizumab for the treatment of neovascular AMD utilizing MARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-Related Macular ... See full document

... intravitreal bevacizumab is a strong competitor for first line of treatment for DME and PDR in ...used bevacizumab in combination with laser photocoagulation (PRP or scatter or focal or grid) in PDR or DME ... See full document

... mixed clinical presentation may occur more often than what expect- ed, and externalizing behaviors should be taken into account for future studies, given the importance they have in perpetuating the interpersonal ... See full document

... the comparison of ranibizumab with conbercept, 3) patients with AMD that required anti-VEGF therapy, and 4) studies that included at least one outcome of interest mentioned below with relative data ... See full document

... were Bevacizumab (2278; 93.2%) and Ranibizumab (165; ...proliferative diabetic retinopathy (PDR) ...proliferative diabetic retinopathy and sickle cell retinopathy ... See full document